Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Overview | 10 | 1 |
| Therapeutics Development | 11 | 5 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Products under Development by Stage of Development | 11 | 1 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Products under Development by Therapy Area | 12 | 1 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Products under Development by Indication | 13 | 3 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Products under Development by Companies | 19 | 9 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Products under Development by Universities/Institutes | 28 | 2 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Therapeutics Assessment | 30 | 7 |
| Assessment by Monotherapy/Combination Products | 30 | 1 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 2 |
| Assessment by Molecule Type | 35 | 2 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Companies Involved in Therapeutics Development | 37 | 19 |
| AB Science SA | 37 | 2 |
| Amgen Inc. | 39 | 1 |
| AstraZeneca Plc | 40 | 1 |
| BCI Pharma | 41 | 1 |
| Chroma Therapeutics Limited | 42 | 1 |
| CTI BioPharma Corp. | 43 | 1 |
| Deciphera Pharmaceuticals, LLC | 44 | 1 |
| Eli Lilly and Company | 45 | 1 |
| F. Hoffmann-La Roche Ltd. | 46 | 1 |
| Five Prime Therapeutics, Inc. | 47 | 1 |
| Ignyta, Inc. | 48 | 1 |
| Johnson &Johnson | 49 | 1 |
| Novartis AG | 50 | 1 |
| Pfizer Inc. | 51 | 1 |
| Plexxikon Inc. | 52 | 2 |
| SignalChem Lifesciences Corp | 54 | 1 |
| Transgene SA | 55 | 1 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Drug Profiles | 56 | 69 |
| AMG-820 Drug Profile | 56 | 1 |
| BLZ-945 Drug Profile | 57 | 1 |
| cediranib maleate Drug Profile | 58 | 3 |
| DCC-3014 Drug Profile | 61 | 1 |
| Drug to Antagonize CSF1R for Malignant Ascites Drug Profile | 62 | 1 |
| emactuzumab Drug Profile | 63 | 1 |
| FPA-008 Drug Profile | 64 | 3 |
| JNJ-28312141 Drug Profile | 67 | 1 |
| JNJ-40346527 Drug Profile | 68 | 1 |
| LY-3022855 Drug Profile | 69 | 1 |
| masitinib Drug Profile | 70 | 14 |
| pacritinib Drug Profile | 84 | 11 |
| pazopanib hydrochloride Drug Profile | 95 | 7 |
| pazopanib hydrochloride + pembrolizumab Drug Profile | 102 | 1 |
| PD-0360324 Drug Profile | 103 | 1 |
| pexidartinib Drug Profile | 104 | 4 |
| PLX-73086 Drug Profile | 108 | 1 |
| PLX-7486 Drug Profile | 109 | 1 |
| RXDX-105 Drug Profile | 110 | 2 |
| Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation Drug Profile | 112 | 1 |
| Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation Drug Profile | 113 | 1 |
| Small Molecules to Antagonize CSF-1 Receptor for Oncology Drug Profile | 114 | 1 |
| Small Molecules to Antagonize CSF-1R for Inflammation Drug Profile | 115 | 1 |
| Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology Drug Profile | 116 | 1 |
| Small Molecules to Inhibit FMS for Rheumatoid Arthritis Drug Profile | 117 | 1 |
| Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases Drug Profile | 118 | 1 |
| sunitinib malate Drug Profile | 119 | 5 |
| TG-3003 Drug Profile | 124 | 1 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Dormant Projects | 125 | 9 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Discontinued Products | 134 | 6 |
| Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Featured News &Press Releases | 140 | 19 |
| Jul 04, 2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA) | 140 | 1 |
| Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting | 140 | 4 |
| Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization | 144 | 1 |
| Jun 05, 2016: Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016 | 145 | 1 |
| May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association | 146 | 1 |
| May 24, 2016: Ignyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting | 147 | 1 |
| May 19, 2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting | 148 | 1 |
| May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis | 149 | 1 |
| May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis | 149 | 1 |
| Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment | 150 | 1 |
| Apr 20, 2016: Deciphera s Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition as a Single Agent and In Combination with an Anti-PD1 Inhibitor | 151 | 1 |
| Apr 13, 2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting | 151 | 1 |
| Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) | 152 | 4 |
| Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, | 156 | 1 |
| Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis | 157 | 2 |
| Appendix | 159 | 2 |
| Methodology | 159 | 1 |
| Coverage | 159 | 1 |
| Secondary Research | 159 | 1 |
| Primary Research | 159 | 1 |
| Expert Panel Validation | 159 | 1 |
| Contact Us | 159 | 1 |
| Disclaimer | 160 | 1 |